At three years, new data showed overall survival and disease-free survival of 63% and 56% respectively
At ten years, follow-up data demonstrated sustained long-term bone marrow recovery
Omidubicel patients reported clinically meaningful health-related quality of life scores compared to umbilical cord blood
Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the presentation of new long term follow-up data and health-related quality of life scores of patients treated with omidubicel at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO), being held in Houston, Texas.
https://finance.yahoo.com/news/long-term-data-omidubicel-phase-110000158.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.